(Q47922360)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

title

New perspectives on CKD-induced dyslipidemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

1 reference

Marcelino Bermúdez-López

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Jose M Valdivielso

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

David Arroyo

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Luís Masana

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

author name string

Àngels Betriu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

Elvira Fernández

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

language of work or name

English

0 references

publication date

28 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Therapeutic Targets

28 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

28 March 2020

page(s)

967-976

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

The Patterns, Risk Factors, and Prediction of Progression in Chronic Kidney Disease: A Narrative Review

28 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Lipoprotein metabolism and lipid management in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Mineral metabolism and cardiovascular disease in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Observational multicenter study to evaluate the prevalence and prognosis of subclinical atheromatosis in a Spanish chronic kidney disease cohort: baseline data from the NEFRONA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Predictors of Subclinical Atheromatosis Progression over 2 Years in Patients with Different Stages of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Association of serum phosphorus with subclinical atherosclerosis in chronic kidney disease. Sex makes a difference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Soluble TWEAK levels predict the presence of carotid atherosclerotic plaques in subjects free from clinical cardiovascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Soluble TWEAK and atheromatosis progression in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Triglycerides and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Lipoprotein metabolism and CKD: overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Dyslipidemia associated with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Dyslipidemia in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Dialysis Modalities and HDL Composition and Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Clinical and research markers of oxidative stress in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Chronic inflammatory disorders and accelerated atherosclerosis: chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Clinical implications of discordance between low-density lipoprotein cholesterol and particle number

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

HDL particle number and size as predictors of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Associations between small dense LDL, HDL subfractions (HDL2, HDL3) and risk of atherosclerosis in Japanese-Americans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Lipidomics applications in health, disease and nutrition research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Metabolomics in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Metabolomics in the study of kidney diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

21 January 2018

Targeted metabolomics

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

A combined non-targeted and targeted metabolomics approach to study the stereoselective metabolism of benalaxyl enantiomers in mouse hepatic microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Statistical methods for the analysis of high-throughput metabolomics data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Metabolomics for clinical use and research in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Metabolic biomarkers for chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Metabolomics insights into activated redox signaling and lipid metabolism dysfunction in chronic kidney disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Metabolomic Signatures of Chronic Kidney Disease of Diverse Etiologies in the Rats and Humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Combined Clinical Phenotype and Lipidomic Analysis Reveals the Impact of Chronic Kidney Disease on Lipid Metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Gene and protein expressions and metabolomics exhibit activated redox signaling and wnt/β-catenin pathway are associated with metabolite dysfunction in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

The link between phenotype and fatty acid metabolism in advanced chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Systems biology of kidney diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Dyslipidemia in patients with chronic kidney disease: etiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14728222.2017.1369961

10.1080/14728222.2017.1369961

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28829206%20AND%20SRC:MED&resulttype=core&format=json

release_nehhnx7p3jafvgkz3y522aa3fy

28 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nehhnx7p3jafvgkz3y522aa3fy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference